Drug Trial Radar · NCT05047185
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Actual
Start
Apr 19, 2022
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- Sep 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study consists of 2 parts, with patients completing participation in Part 1 prior to initiation of treatment in Part 2. Part 1 of the study has 3 parallel arms and approximately 30 patients will be equally randomized to one of two dose regimens of PHA-022121 or matching placebo. Patients will continue to the single open-label arm in Part 2 of the study after completion of Part 1. The screening period is up to 8 weeks and the treatment periods are 12 weeks (Part 1) and 30 months (Part 2) in duration.
Conditions
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor Deficiency
- C1 Inhibitor Deficiency
Interventions
Deucrictibant low doseDrug
Deucrictibant softgel capsules for oral use (PHVS416)
Deucrictibant high doseDrug
Deucrictibant softgel capsules for oral use (PHVS416)
PlaceboDrug
Matching placebo capsules for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Investigator-confirmed Hereditary Angioedema (HAE) Attacks (Expressed as the Normalized Number of Attacks Per Month [4 Weeks] of Exposure) During the Treatment Period in Part 1Time frame: Up to Day 84
Locations
19 sites in 9 countries. Site status is shown where the registry gives one.
Study site
Birmingham, Alabama
Study site
Paradise Valley, Arizona
Study site
St Louis, Missouri
Study Site
Vienna, Austria
Study site
Sofia, Bulgaria
Study site
Ottawa, Ontario, Canada
Study site
Montreal, Quebec, Canada
Study site
Berlin, Germany
Study site
Frankfurt, Germany
Study site
Dublin, Ireland
Study site
Milan, Italy
Study site
Palermo, Italy
Study site
Padua, PD, Italy
Study site
Krakow, Poland
Study site
Brighton, England, United Kingdom
Study site
Bristol, England, United Kingdom
Study site
Cambridge, England, United Kingdom
Study site
London, England, United Kingdom
Study site
Southampton, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.